

# CITATION REPORT

List of articles citing

**Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis**

**DOI: 10.1007/s40261-013-0144-3**

**Clinical Drug Investigation, 2014, 34, 9-17.**

**Source:** <https://exaly.com/paper-pdf/58796248/citation-report.pdf>

**Version:** 2024-04-18

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
46	Novel oral anticoagulants in non-valvular atrial fibrillation. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , <b>2014</b> , 12, 3-8	1.9	17
45	Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. <i>American Journal of Cardiovascular Drugs</i> , <b>2014</b> , 14, 451-62	4	31
44	Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence. <i>Expert Review of Cardiovascular Therapy</i> , <b>2014</b> , 12, 933-47	2.5	5
43	Analisi di costo efficacia dei nuovi anticoagulanti orali nella prevenzione dell'ictus in pazienti con fibrillazione atriale non valvolare in Italia. <i>Pharmacoeconomics Italian Research Articles</i> , <b>2014</b> , 16, 1		3
42	Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany. <i>BioMed Research International</i> , <b>2015</b> , 2015, 876923	3	16
41	From decision to shared-decision: Introducing patients' preferences into clinical decision analysis. <i>Artificial Intelligence in Medicine</i> , <b>2015</b> , 65, 19-28	7.4	21
40	Graphical representation of life paths to better convey results of decision models to patients. <i>Medical Decision Making</i> , <b>2015</b> , 35, 398-402	2.5	9
39	Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 39, 149-54	5.1	28
38	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. <i>Europace</i> , <b>2015</b> , 17, 1007-17	3.9	40
37	Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. <i>Advances in Therapy</i> , <b>2015</b> , 32, 216-27	4.1	23
36	Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation. <i>Current Cardiology Reports</i> , <b>2015</b> , 17, 61	4.2	11
35	Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. <i>Pharmacoeconomics</i> , <b>2015</b> , 33, 271-83	4.4	14
34	Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAf) in the US. <i>ClinicoEconomics and Outcomes Research</i> , <b>2016</b> , 8, 215-26	1.7	13
33	Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis. <i>International Forum of Allergy and Rhinology</i> , <b>2016</b> , 6, 582-9	6.3	22
32	Anticoagulants d'action directe: une revue de la littérature des études de coût/efficacité en Europe. <i>Archives of Cardiovascular Diseases Supplements</i> , <b>2016</b> , 8, 180-191	0.3	1
31	Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. <i>Stroke</i> , <b>2016</b> , 47, 1555-61	6.7	37
30	The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015. <i>Acta Pharmaceutica Sinica B</i> , <b>2016</b> , 6, 522-530	15.5	43

29	A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation. <i>Cardiology and Therapy</i> , <b>2016</b> , 5, 171-186	2.8	15
28	Stakeholders in non-Vitamin K antagonist oral anticoagulants prescription: the case of Italy. <i>Europace</i> , <b>2016</b> , 18, 788	3.9	2
27	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2016</b> , 16, 221-35	2.2	16
26	Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , <b>2017</b> , 17, 15	2.3	8
25	Artificial Intelligence in Medicine. <i>Lecture Notes in Computer Science</i> , <b>2017</b> ,	0.9	0
24	Latin American Clinical Epidemiology Network Series - Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile. <i>Journal of Clinical Epidemiology</i> , <b>2017</b> , 86, 75-83	5.7	6
23	The impact of asthma on the cost effectiveness of surgery for chronic rhinosinusitis with nasal polyps. <i>International Forum of Allergy and Rhinology</i> , <b>2017</b> , 7, 1035-1044	6.3	8
22	Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis. <i>Laryngoscope</i> , <b>2017</b> , 127, 29-37	3.6	30
21	Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed. <i>BMC Cardiovascular Disorders</i> , <b>2017</b> , 17, 260	2.3	3
20	Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Retrospective Population Study. <i>Medical Care</i> , <b>2018</b> , 56, 410-415	3.1	2
19	The value of frontal sinusotomy for chronic rhinosinusitis with nasal polyps-A cost utility analysis. <i>Laryngoscope</i> , <b>2018</b> , 128, 43-51	3.6	9
18	THE GAP BETWEEN ECONOMIC EVALUATIONS AND CLINICAL PRACTICE: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS ON DABIGATRAN FOR ATRIAL FIBRILLATION. <i>International Journal of Technology Assessment in Health Care</i> , <b>2018</b> , 34, 327-336	1.8	1
17	New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222762	3.7	6
16	Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding. <i>Pharmacoeconomics</i> , <b>2019</b> , 37, 279-289	4.4	6
15	Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation. <i>Heart Lung and Circulation</i> , <b>2020</b> , 29, 390-400	1.8	11
14	Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting. <i>Journal of Medical Economics</i> , <b>2020</b> , 23, 252-261	2.4	4
13	The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France. <i>European Journal of Health Economics</i> , <b>2020</b> , 21, 235-249	3.6	6
12	Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles. <i>Pharmacoeconomics</i> , <b>2020</b> , 38, 1333-1343	4.4	2

11	Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps. <i>Laryngoscope</i> , <b>2021</b> , 131, E26-E33	3.6	33
10	A Platform for Targeting Cost-Utility Analyses to Specific Populations. <i>Lecture Notes in Computer Science</i> , <b>2017</b> , 361-365	0.9	2
9	Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. <i>Health Technology Assessment</i> , <b>2017</b> , 21, 1-386	4.4	90
8	Practical issues in the management of novel oral anticoagulants-cardioversion and ablation. <i>Journal of Thoracic Disease</i> , <b>2015</b> , 7, 115-31	2.6	8
7	Cost-Effectiveness Analysis of Oral Anticoagulants in Stroke Prevention among Patients with Atrial Fibrillation in Taiwan. <i>Acta Cardiologica Sinica</i> , <b>2020</b> , 36, 50-61	1.1	3
6	Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. <i>BMJ Evidence-Based Medicine</i> , <b>2021</b> ,	2.7	4
5	Pharmacoeconomics. <b>2020</b> , 1-135		
4	Pharmacoeconomics. <b>2022</b> , 101-234		0
3	Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Economic Evaluations. <b>2023</b> , 33, 99-108		0
2	Cost-Effectiveness of Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation in Hong Kong. <b>2023</b> , 36, 51-57		0
1	A Review on the Green Synthesis of Benzimidazole Derivatives and Their Pharmacological Activities. <b>2023</b> , 13, 392		1